Modality Solutions has announced its sponsorship and roundtable leadership at the 17th Annual World Vaccine Congress (WVA) in Washington, DC.
Taking place from 10 April 10 to12 April at the Grand Hyatt, the congress promotes research, development, and strategic partnering for the global vaccine industry.
Principal at Modality Solutions Daniel Littlefield will lead an interactive roundtable discussion on the first day at 11:20. Titled ‘Managing Your Cold Chain – Lessons Learned from the Ebola Clinical Trials’, Littlefield will cover the topic, ‘Are you effectively managing temperature requirements in your clinical trials in Zone 4 climate zones?’.
The discussion will include management of multiple temperature ranges from <-60°C to 8°C, transport and storage with minimal infrastructure to remote depots and clinical trial sites, and compliance by partnering with the local regulatory authorities.
Daniel said: "I invite Congress attendees to join my interactive roundtable.
"Come and learn practical solutions for the real-world challenges that led to a flawless execution of the STRIVE Ebola clinical trial in sub-Saharan Africa with zero temperature excursions."
Modality Solutions’ president Gary Hutchinson said: "Our sponsorship and participation in the WVA supports our continued commitment to work with vaccine experts from top pharmaceutical and biotechnology companies worldwide.
"The congress will cover some of the crucial technological developments that are changing how vaccines are researched, manufactured, and distributed."
WVA Washington is well-established as one of the leading events on vaccines each year. Now in its seventeenth year, attendees are guaranteed one of the best experiences on-site.
The congress will cover crucial topics affecting the whole sector. Leadership anticipates more than 700 senior vaccine executives will take advantage of the event and eight co-located streams on immune profiling, cancer and immunotherapy, influenza and respiratory, clinical trials, emerging diseases, partnerships, veterinary vaccines, and bioprocessing and manufacturing.